Last reviewed · How we verify
SCH 39641
SCH 39641 is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce inflammatory responses.
SCH 39641 is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce inflammatory responses. Used for Asthma, Allergic rhinitis.
At a glance
| Generic name | SCH 39641 |
|---|---|
| Also known as | MK-3641 |
| Sponsor | ALK-Abelló A/S |
| Drug class | Leukotriene receptor antagonist |
| Target | Cysteinyl leukotriene receptors (CysLT1/CysLT2) |
| Modality | Biologic |
| Therapeutic area | Immunology / Respiratory |
| Phase | Phase 3 |
Mechanism of action
The drug works by antagonizing cysteinyl leukotriene receptors (CysLT1 and/or CysLT2), which are key mediators of inflammation and bronchoconstriction in allergic and asthmatic conditions. By blocking these receptors, SCH 39641 reduces the recruitment and activation of inflammatory cells, decreasing airway inflammation and improving airflow obstruction.
Approved indications
- Asthma
- Allergic rhinitis
Common side effects
- Headache
- Nausea
- Dyspepsia
- Elevated liver enzymes
Key clinical trials
- A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751) (PHASE3)
- Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081) (PHASE2)
- Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED) (PHASE2, PHASE3)
- Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCH 39641 CI brief — competitive landscape report
- SCH 39641 updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI